https://www.selleckchem.com/products/nx-5948.html
To evaluate the real-world performance of the MiniMed 670G system in Europe, in individuals with diabetes. Data uploaded from October 2018 to July 2020 by individuals living in Europe were aggregated and retrospectively analysed. The mean glucose management indicator (GMI), percentage of time spent within (TIR), below (TBR) and above (TAR) glycaemic ranges, system use and insulin consumed in users with 10or more days of sensor glucose data after initial Auto Mode start were determined. Another analysis based on suboptimally (GMI 8.
Like
Comment
Share
